Alpha Cognition Announces Marketed Offering

NOT FOR DISSEMINATION IN THE UNITED STATES
OR THROUGH U.S. NEWSWIRE SERVICES

VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG) (OTCQB: ACOGF), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce it has commenced a marketed public offering (the “Offering”) of units (the “Units”) for up to $10 million.